U.S. FDA places Mersana's cancer drug trial on hold following death
Send a link to a friend
[March 14, 2023]
(Reuters) - Mersana Therapeutics Inc said on Monday the U.S. drug
regulator had placed on hold an early-stage trial testing its
experimental cancer drug after the death of a participant.
The death was of a patient enrolled at the initial dose level in the
dose escalation portion, the company said.
The study was testing the company's XMT-2056 candidate.
The company is now focused on analyzing the death and "consider
potential next steps for development,” Chief Executive Officer Anna
Protopapas said in a statement.
[to top of second column]
|
![](http://archives.lincolndailynews.com/2023/Mar/14/images/031323PIX/graue_lda_preowned_031323.jpg) The company will continue to make
progress with the other cancer drug candidate UpRi and XMT-1660
clinical trials.
Shares of Mersana were halted before the bell.
(Reporting by Leroy Leo and Khushi Mandowara in Bengaluru; Editing
by Sriraj Kalluvila)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |